ArticleInfection and drug resistance2025
Antimicrobial Resistance Surveillance of Skin and Soft Tissue Infections: Hospital-Wide Bacterial Species and Antibiograms to Inform Management at a Zonal Tertiary Hospital in Mwanza, Tanzania.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of antimicrobial resistance in Tanzania: A systematic review and meta-analysis.PloS one · 2026Pooled it
- Safety and Effectiveness of a Fixed-Dose Combination of Cephalexin Extended Release and Clavulanate Potassium in Bacterial Sore Throat and Uncomplicated Skin and Soft-Tissue Infections: A Multicentre, Open-Label, Phase IV Study in India.Drugs - real world outcomes · 2026Article
- Evolution in Epidemiology and Antimicrobial Resistance Patterns of Bacteria Among Dermatology Patients: A Retrospective Study in a Tertiary Dermatology Hospital in China (2018-2023).Infection and drug resistance · 2026Article
- Rose Bengal-Incorporated Supramolecular Gels as a Topical Platform for Localized Antimicrobial Photodynamic Therapy.International journal of molecular sciences · 2025Article
- Necrotizing Fasciitis: A Retrospective Review of the Microbiological Aspects and Factors Associated with Multi-Drug Resistance from a Saudi Tertiary Care Hospital.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The National Action Plan on antimicrobial resistance (NAP-AMR) in Tanzania is focused on blood stream infections and urinary tract infections despite skin and soft tissue infections (SSTIs) being common. This study assessed the proportion of laboratory-confirmed SSTIs, identify bacterial species involved, analyze AMR phenotypes, and investigate the risk factors associated with multidrug-resistant (MDR) SSTIs. Patients and Methods: Analytical cross-sectional study was conducted between January and June 2023, involving 614 patients with SSTIs. Patients' information was collected using standard AMR surveillance tools, and either pus swabs or pus aspirate or necrotic tissues were collected and analyzed using standard microbiological procedures, WHONET and STATA software programs. Results: The median age (interquartile range) of patients was 34 (14-54) years with males accounting for 54.4%. Laboratory-confirmed SSTIs was 72.5% (445/614), yielding 586 bacterial isolates. The most frequent SSTIs types were surgical site infections (30.0%), chronic wounds (27.9%), and traumatic wounds (19.7%). The commonest pathogens were Conclusion: Approximately three-quarter of patients have laboratory-confirmed SSTIs caused predominantly by MDR pathogens. Revisiting SSTIs treatment guidelines at BMC and inclusion of SSTIs in the on-going AMR surveillance in Tanzania are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.